bilastine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG PubChem repoDB

Active Ingredient History

NOW
  • Now
Bilastine is an antihistamine medication used to treat hives (urticaria) and inflammation of the eye (allergic conjunctivitis) caused by an allergy. It is a second-generation antihistamine and takes effect by selectively inhibiting the histamine H1 receptor, preventing these allergic reactions. Bilastine has an effectiveness similar to cetirizine, fexofenadine, and desloratadine. It was originally developed in Spain by FAES Farma.   Wikipedia

Chemistry

  • SMILES: CCOCCn1c(nc2ccccc12)C3CCN(CCc4ccc(cc4)C(C)(C)C(=O)O)CC3
  • InChIKey: ACCMWZWAEFYUGZ-UHFFFAOYSA-N
  • Mol. Mass: 463.62
  • ALogP: 4.86
  • ChEMBL Molecule:
    bilastine  
More Chemistry

Pharmacology

Alternative names

bellozal | bilastine | bilaxten | f-96221-bm1 | ilaxten

Organizations (31)

Research & Development (31)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Asthma (Phase 4)

Chronic Urticaria (Phase 3)

Conjunctivitis (Phase 4)

Conjunctivitis, Allergic (Phase 3)

Healthy Volunteers (Phase 1)

Hypersensitivity (Phase 2)

Pharmacokinetics (Phase 1)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Perennial (Phase 3)

Rhinitis, Allergic, Seasonal (Phase 4)

Urticaria (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 23
  • # of Trial Organizations: 31

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue